Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTL Therapy and Radiation for Esophageal Cancer
NCT03011255Phase 2Unknown
- Sponsor
- Hangzhou Cancer Hospital
- Start
- Dec 2016
- Primary completion
- Aug 2017
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of peptide-specific cytotoxic T-lymphocytes in esophageal cancer, sponsored by Hangzhou Cancer Hospital. Status: unknown.
02
Drugs
peptide-specific cytotoxic T-lymphocytes
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on NCT03011255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03011255.